title: Expression of HLA-DR, CD80, and CD86 in Healthy Aging and Alzheimer's Disease.
abstract: Although monocytes and macrophages could serve as new therapeutic targets for treatment of Alzheimer's disease (AD) and aging of the human innate immune system, its role in the pathogenesis of neurodegenerative disorders such as AD are only poorly understood. We have addressed this here by determining the number of CD14+ monocytes and the frequency of HLA-DR-, CD80-, and CD86-expression in peripheral blood from healthy volunteers aged 20-79 years, and in AD patients at diagnosis and after 12, 30, and 52 weeks of rivastigmine treatment. While the number of CD14+ monocytes remained constant, the expression of HLA-DR, CD80, and CD86 by monocytes increased with age. However, no differences were identified by comparing AD patients with age-matched healthy controls or following treatment of AD patients with rivastigmine. These results indicate that changes in the expression of HLA-DR, CD80, and CD86 are caused by immunosenescence rather than by AD pathology or treatment of AD patients with rivastigmine.
authors.affiliation: Department of Psychiatry, University of Magdeburg, Magdeburg, Germany.
authors.forename: Stefan
authors.initials: S
authors.lastname: Busse
authors.affiliation: Department of Psychiatry, University of Magdeburg, Magdeburg, Germany.|Center for Behavioral Brain Sciences, Magdeburg, Germany.
authors.forename: Johann
authors.initials: J
authors.lastname: Steiner
authors.affiliation: Department of Psychiatry, University of Magdeburg, Magdeburg, Germany.
authors.forename: Juliane
authors.initials: J
authors.lastname: Alter
authors.affiliation: Department of Psychiatry, University of Magdeburg, Magdeburg, Germany.
authors.forename: Henrik
authors.initials: H
authors.lastname: Dobrowolny
authors.affiliation: Department of Neuropathology, University of Magdeburg, Magdeburg, Germany.
authors.forename: Christian
authors.initials: C
authors.lastname: Mawrin
authors.affiliation: Department of Psychiatry, University of Magdeburg, Magdeburg, Germany.|Center for Behavioral Brain Sciences, Magdeburg, Germany.
authors.forename: Bernhard
authors.initials: B
authors.lastname: Bogerts
authors.affiliation: Institute of Immunology, University of Magdeburg, Magdeburg, Germany.
authors.forename: Roland
authors.initials: R
authors.lastname: Hartig
authors.affiliation: Department of Pediatric Pulmonology, Allergology & Neonatology, Medical University of Hannover, Hannover, Germany.
authors.forename: Mandy
authors.initials: M
authors.lastname: Busse
mesh_terms: D000328:Adult; D000368:Aged; D000375:Aging / Q000235:genetics*; D000544:Alzheimer Disease / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology*; D000704:Analysis of Variance; D015703:Antigens, CD / Q000378:metabolism*; D018122:B7-1 Antigen / Q000378:metabolism; D051940:B7-2 Antigen / Q000378:metabolism; D002800:Cholinesterase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D006684:HLA-DR Antigens / Q000378:metabolism*; D006801:Humans; D018950:Lipopolysaccharide Receptors / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D009000:Monocytes / Q000378:metabolism*; D000068836:Rivastigmine / Q000494:pharmacology / Q000627:therapeutic use; D055815:Young Adult
chemical_list: D015703:Antigens, CD; D018122:B7-1 Antigen; D051940:B7-2 Antigen; D002800:Cholinesterase Inhibitors; D006684:HLA-DR Antigens; D018950:Lipopolysaccharide Receptors; D000068836:Rivastigmine
keywords: Alzheimer’s disease; CD80; CD86; HLA-DR; monocytes